This article needs additional citations for
verification. (October 2021) |
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Remodulin, Orenitram, Tyvaso, others |
AHFS/ Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous, intravenous, inhalation, by mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~100% |
Metabolism | Substantially metabolized by the liver |
Elimination half-life | 4 hours |
Excretion | Urine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.236.149 |
Chemical and physical data | |
Formula | C23H34O5 |
Molar mass | 390.520 g·mol−1 |
| |
![]() ![]() |
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of pulmonary arterial hypertension. [6]
Treprostinil was approved for use in the United States in May 2002. [7]
Treprostinil is indicated for the treatment of pulmonary arterial hypertension in people with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. [1]
Common side effects depending on route of administration:
Treprostinil may be administered as a continuous subcutaneous infusion or continuous intravenous infusion. [1]
The inhaled form of treprostinil was approved by the FDA in July 2009, and is sold under the brand name Tyvaso. [3] [4]
The oral form of treprostinil was approved by the FDA in December 2013, and is sold under the brand name Orenitram. [2]
During the 1960s a UK research team, headed by Professor John Vane began to explore the role of prostaglandins in anaphylaxis and respiratory diseases. Working with a team from the Royal College of Surgeons, Vane discovered that aspirin and other oral anti-inflammatory drugs worked by inhibiting the synthesis of prostaglandins. This finding opened the door to a broader understanding of the role of prostaglandins in the body.
Vane and a team from the Wellcome Foundation had identified a lipid mediator they called “PG-X,” which inhibited platelet aggregation. PG-X, which later would become known as prostacyclin, was 30 times more potent than any other known anti-aggregatory agent.[ citation needed]
By 1976, Vane and fellow researcher Salvador Moncada published the first paper on prostacyclin, in the scientific journal Nature. [9]
Treprostinil (Remodulin) was approved for use in the United States in May 2002, [1] [7] and again in July 2018. [10] Tyvaso, the inhaled form of treprostinil, was approved for use in the United States in July 2009. [11] Orenitram was approved in December 2013. [12]
Treprostinil (Trepulmix) was approved for use in the European Union in April 2020. [5]
Treprostinil therapy may be effective in treating Degos disease. [13]
This article needs additional citations for
verification. (October 2021) |
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Remodulin, Orenitram, Tyvaso, others |
AHFS/ Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous, intravenous, inhalation, by mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~100% |
Metabolism | Substantially metabolized by the liver |
Elimination half-life | 4 hours |
Excretion | Urine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.236.149 |
Chemical and physical data | |
Formula | C23H34O5 |
Molar mass | 390.520 g·mol−1 |
| |
![]() ![]() |
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of pulmonary arterial hypertension. [6]
Treprostinil was approved for use in the United States in May 2002. [7]
Treprostinil is indicated for the treatment of pulmonary arterial hypertension in people with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. [1]
Common side effects depending on route of administration:
Treprostinil may be administered as a continuous subcutaneous infusion or continuous intravenous infusion. [1]
The inhaled form of treprostinil was approved by the FDA in July 2009, and is sold under the brand name Tyvaso. [3] [4]
The oral form of treprostinil was approved by the FDA in December 2013, and is sold under the brand name Orenitram. [2]
During the 1960s a UK research team, headed by Professor John Vane began to explore the role of prostaglandins in anaphylaxis and respiratory diseases. Working with a team from the Royal College of Surgeons, Vane discovered that aspirin and other oral anti-inflammatory drugs worked by inhibiting the synthesis of prostaglandins. This finding opened the door to a broader understanding of the role of prostaglandins in the body.
Vane and a team from the Wellcome Foundation had identified a lipid mediator they called “PG-X,” which inhibited platelet aggregation. PG-X, which later would become known as prostacyclin, was 30 times more potent than any other known anti-aggregatory agent.[ citation needed]
By 1976, Vane and fellow researcher Salvador Moncada published the first paper on prostacyclin, in the scientific journal Nature. [9]
Treprostinil (Remodulin) was approved for use in the United States in May 2002, [1] [7] and again in July 2018. [10] Tyvaso, the inhaled form of treprostinil, was approved for use in the United States in July 2009. [11] Orenitram was approved in December 2013. [12]
Treprostinil (Trepulmix) was approved for use in the European Union in April 2020. [5]
Treprostinil therapy may be effective in treating Degos disease. [13]